Mr. Speaker, it is always an honour to rise in the House to speak on behalf of the constituents of my riding of Pitt Meadows—Maple Ridge. Today, I rise to speak in support of Bill C-37, an act to amend the Controlled Drugs and Substances Act and to make related amendments to other acts.
The bill is particularly important for my community and the communities in the greater Vancouver region that have been facing a crisis of such horrific and disturbing magnitude. To date, over 1,000 children, mothers, fathers, brothers, and sisters have died from the opioid crisis in our region. These are not numbers. These are people and victims of addiction, each with their own incredibly painful story.
In my riding we are facing a homelessness crisis. To live in the midst of a riding that is facing an unprecedented number of homeless and drug addicted members of the community, we know first-hand that these are folks who are battling serious mental illnesses with very few to no resources. In crafting the bill, we are doing so with an understanding that addiction is a health problem.
To quote the hon. Minister of Health, “Addiction is not a crime. Addiction is not a mark of moral failure. It is a health issue. For many, it is a mechanism to manage unbearable pain, an attempt to relieve suffering when life offers few alternatives”.
For too long we have not been paying attention to the closely tied relationship between drug addiction and mental health. Too many people in our communities are sick and our policies must begin to reflect this.
Protecting the health and safety of Canadians is a key priority for this government. That is why on December 12, 2016, the Minister of Health, with support from the Minister of Public Safety, took action to end this crisis and introduce policies that get serious about ending drug addiction in Canada.
The bill supports our government's goal of creating a comprehensive, collaborative, compassionate, and evidence-based approach to drug policy in Canada. It aims to balance the important objectives of protecting public health and maintaining public safety. Bill C-37 would better equip both health and law enforcement officials with the tools they need to reduce the harms associated with drug and substance use in Canada.
Specifically, the bill would improve the government's ability to support the establishment of supervised consumption sites as a key harm reduction measure; address the illegal supply, production, and distribution of drugs; and reduce the risk of controlled substances used for legitimate purposes being diverted to the illegal market by improving compliance and enforcement tools.
While all aspects of the bill are important, I would like to focus my remarks today on how the bill would modernize the Controlled Drugs and Substances Act to strengthen law enforcement and the government's ability to monitor, promote, and enforce compliance. This would reduce the risk of diversion of controlled substances that are used for legitimate purposes, such as prescription opioids, to the illegal market. This is a pressing concern as the diversion of controlled substances to the illicit market contributes to problematic substance use in Canada.
The Controlled Drugs and Substances Act came into force in 1997. While it has been amended over the years, it has not kept pace with the significant changes seen in the illicit controlled substances industry and the illicit drug market. In particular, the current troubling and growing rates of opioid overdoses and deaths highlight certain gaps and weaknesses within the existing legislation.
Bill C-37 would modernize compliance and enforcement powers by improving inspection authorities by bringing them in line with authorities in other federal legislation. Under the Controlled Drugs and Substances Act, Health Canada regulates more than 600 licensed dealers who manufacture, buy, sell, distribute, import, export, and transport controlled substances for legitimate purposes. At present, Health Canada's inspectors are only able to inspect sites where authorized activities with controlled substances and precursors are taking place.
This bill proposes to allow Health Canada inspectors to enter places where they believe, on reasonable grounds, that activities with controlled substances or precursors are taking place. For example, Health Canada would be able to inspect establishments whose licences to conduct activities with controlled substances have been suspended or revoked to verify that illegal activities are not taking place.
To be clear, the proposed inspection authorities would not allow inspectors to enter private dwellings without the consent of an occupant or a warrant. As always, should Health Canada inspectors believe that illicit activities with controlled substances are taking place, they would refer the case to law enforcement officers.
Bill C-37 would also improve compliance and enforcement under the Controlled Drugs and Substances Act by providing the Minister of Health the authority to compel regulated parties or persons importing a designated device to provide information regarding their activities. This authority could be used in only two circumstances: to verify compliance or prevent non-compliance with the act, or to address a risk to public health or public safety. Having access to timely information would alert the minister to potential diversion risks and improve the minister's ability to address a public health or safety threat. This authority is in line with other modern federal legislation, such as the Food and Drugs Act.
This bill also provides for an administrative monetary penalty scheme. Currently, Health Canada has limited options to address non-compliance within the Controlled Drugs and Substances Act. Health Canada can send a warning letter, which may not be effective at resolving a non-compliance situation, or suspend or revoke a licence. However, licence suspension or revocation is often considered to be a disproportionate penalty and may not always be appropriate or in the public interest. For example, revocation of a pharmaceutical company's licence could result in a shortage of critical drugs used in medical care.
Further, not all regulated parties are issued licences under the Controlled Drugs and Substances Act. For example, pharmacists, health care practitioners, and hospitals are subject to specific requirements set out in regulations under the act but are not licensed per se.
The introduction of an administrative monetary penalty scheme would offer Health Canada a greater range of tools to promote compliance with the act and its regulations. For example, regulated parties could be liable to pay a fine in cases where they do not follow the required security or record-keeping procedures. While exercising this authority will require regulations, the bill provides a legislative authority to introduce an administrative monetary penalty scheme.
Another aspect of this bill would introduce a new, expedited process for the disposal of seized controlled substances, precursors, and chemical offence-related property whose storage or handling poses a risk to health and safety. The current rules related to the handling and disposal of seized controlled substances, precursors, and other drug-related property are cumbersome and complex. Law enforcement agencies must seek a court order and approval from Health Canada before they dispose of these items, which takes time. This results in large quantities of controlled substances, potentially dangerous chemicals, and other offence-related property needing to be stored for longer periods of time. This poses a risk to public health and public safety. It is also costly, particularly for law enforcement.
The new process proposed in this bill would not require a court order for the disposal of controlled substances, nor for precursors and chemical offence-related property that pose a risk to health and safety. This would therefore reduce the burden on courts, government, and law enforcement agencies.
As members can see, this integrated approach puts evidence-based public health and public safety measures at the forefront of our drug policy here in Canada. Tackling this crisis will require commitment and innovation from all levels of government: federal, provincial, and municipal. We must work together in solidarity to put an end to this crisis that is tearing at our communities and taking lives.
I encourage all members of this House to put saving lives and securing our communities before ideology. I ask all members to support Bill C-37, to stand up for the best interests of our communities, and be part of ushering in a new era of evidence-based drug policy.